Published in

Wiley, Annals of Neurology, 2(49), p. 260-263, 2001

DOI: 10.1002/1531-8249(20010201)49:2<260::aid-ana49>3.0.co;2-y

Wiley, Annals of Neurology, 2(49), p. 260-263

DOI: 10.1002/1531-8249(20010201)49:2<260::aid-ana49>3.3.co;2-p

Links

Tools

Export citation

Search in Google Scholar

Propofol in subanesthetic doses terminates status epilepticus in a rodent model

Journal article published in 2001 by Martin Holtkamp Md, Xin Tong Md, Martin Holtkamp, Xin Tong, Matthew C. Walker ORCID, Walker Mc
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Status epilepticus is commonly refractory to first-line therapy, and thus better treatments are needed. We have investigated an experimental model of drug-resistant self-sustaining status epilepticus (SSSE) induced by 2 hours of perforant path stimulation. Propofol in subanesthetic doses administered shortly after the end of stimulation and also after a further 3 hours of SSSE terminated the SSSE without recurrence. This finding calls for a trial of propofol in refractory status epilepticus and also raises the possibility of using it as first-line therapy. Ann Neurol 2001;49:260–263